{"id":"https://genegraph.clinicalgenome.org/r/42806e76-6460-45c8-95b1-2a7e871bb083v2.1","type":"EvidenceStrengthAssertion","dc:description":["ATRX, which encodes a chromatin remodeler, was first reported in relation to X-linked ATR-X-related syndrome in 1995 (Gibbons et al., PMID: 7697714). X-linked alpha thalassaemia intellectual disability (ATR-X) syndrome in males is associated with profound intellectual disability, facial dysmorphism, genital abnormalities, and alpha thalassaemia. Alpha thalassaemia is observed in approximately 75% of affected individuals. Female carriers are typically unaffected, and have skewed X inactivation. Seven variants (2 missense, 2 nonsense, 1 frameshift, 1 canonical splice site, and 1 near splice site) that have been reported in 10 probands in 6 publications (PMIDs: 7697714, 10204841, 11559911, 20500465, 23681356, 24805811) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The mechanism of pathogenicity is loss of function. This gene-disease relationship is also supported by two knockout mouse models, and a physical association with MECP2, involved in Rett syndrome (PMIDs: 15668733, 20865721, 21209221, 17296936). In summary, there is definitive evidence to support the relationship between ATRX and ATR-X-related syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on April 27, 2018. It was recurated on September 29, 2021, and as a result of this re-evaluation, the classification did not change.","*ATRX*, which encodes a chromatin remodeler, was first reported in relation to X-linked ATR-X-related syndrome in 1995 (Gibbons et al., PMID: 7697714). X-linked alpha thalassaemia intellectual disability (ATR-X) syndrome in males is associated with profound intellectual disability, facial dysmorphism, genital abnormalities, and alpha thalassaemia. Alpha thalassaemia is observed in approximately 75% of affected individuals. Female carriers are typically unaffected, and have skewed X inactivation.\n\nSeven variants (2 missense, 2 nonsense, 1 frameshift, 1 canonical splice site, and 1 near splice site) that have been reported in 10 probands in 6 publications (PMIDs: 7697714, 10204841, 11559911, 20500465, 23681356, 24805811) are included in this curation. More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The mechanism of pathogenicity is loss of function. This gene-disease relationship is also supported by two knockout mouse models, and a physical association with MECP2, involved in Rett syndrome (PMIDs: 15668733, 17296936, 20865721, 21209221).\n\nIn summary, there is definitive evidence supporting the relationship between *ATRX* and ATR-X-related syndrome. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This gene-disease pair was originally evaluated by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on April 27, 2018. It was recurated on September 29, 2021, and as a result of this re-evaluation, the classification did not change."],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/42806e76-6460-45c8-95b1-2a7e871bb083","GCISnapshot":"https://genegraph.clinicalgenome.org/r/5296ecdf-b709-47bd-9032-daec8b91e300","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/5296ecdf-b709-47bd-9032-daec8b91e300_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-08-07T11:45:40.281Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/5296ecdf-b709-47bd-9032-daec8b91e300_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":["2021-09-29T16:00:00.000Z","2021-09-28T22:00:00.000Z"],"role":"Approver"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5296ecdf-b709-47bd-9032-daec8b91e300_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5296ecdf-b709-47bd-9032-daec8b91e300_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/518411de-c762-4501-93f8-a5929e5ada47","type":"EvidenceLine","dc:description":"The authors used three different methods including Y2H, GST pull down, and coimmunoprecipitation to show and confirm the interaction. Furthermore, they showed that patient derived mutations in MECP2 associated with Rett syndrome perturb the interaction, thus showing some significance to disease (albeit more directly for Rett syndrome than ATR-X-related syndrome).","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/764459ad-ad14-471d-846e-5b3e9e006d20","type":"Finding","dc:description":"The N-terminal region of rat MECP2 was used as the bait in the Y2H assay, and a human fetal brain library was probed. Twelve clones for ATRX were verified. The region of interaction was between the N-terminal region of MECP2 (AA 108-169, in the methyl CpG-binding domain) and the C-terminal half of ATRX (c.2010-2280). To confirm that interaction GST-pulldown assays were performed in vitro with mouse brain extract, and they found that ATRX was pulled down, indicating that ATRX is part of a complex with MECP2 in mouse brain. Further confirmation was shown by co-transfection of tagged MECP2 and ATRX in mouse L cells, followed by immunoprecipitation, which showed co-precipitation of ATRX with MECP2. This interaction was abolished when patient derived mutations were introduced into MECP2.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17296936","rdfs:label":"ATRX interacts with MECP2","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5296ecdf-b709-47bd-9032-daec8b91e300_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4ae3446f-d625-42af-a8b9-aa87b1aac6d5","type":"EvidenceLine","dc:description":"The mice showed change in one learning and memory paradigm, but failed to show any impairment in other paradigms. The mice also exhibited reduced LTP in the hippocampus. A total of 2 points were given to the Atrx exon 2 deletion mice, 1 for abnormal behavior and LTP (this reference) and 1 for aberrant dendritic spines and CaMKII activity (PMID: 21209221).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5089a2b3-c588-47cb-ab08-2a937bb68a6a","type":"Finding","dc:description":"This Atrx exon2 deletion mouse shows impairments in learning in the contextual fear memory paradigm. The wild-type had freezing following the cue, whereas Atrx exon 2 deletion mice had impaired freezing, suggesting that they were unable to couple the cue with an negative outcome. However, the Atrx exon 2 deletion mice failed to show any changes in learning and memory in the Morris Water maze task. The mice also showed reduced LTP in the hippocampus. The reduction in LTP was abated by the NMDAR antagonist APV, suggesting that the change was mediated by NMDA signaling.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20865721","rdfs:label":"Atrx exon 2 deletion mice-behavior","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/141df5a0-6473-4315-a334-8b135e2eb6d9","type":"EvidenceLine","dc:description":"A total of 2 points were given to the Atrx exon 2 deletion mice, 1 for abnormal behavior and LTP (PMID: 20865721) and 1 for aberrant dendritic spines and CaMKII activity (this reference).","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/86ae4282-f4ed-4bbe-9c84-13bd1cac6eba","type":"Finding","dc:description":"ATRX mutant mice lacking exon 2 exhibited abnormal dendritic spine formation in the medial prefrontal cortex (mPFC), with longer and thinner spines compared with wild-type mice, without changes in spine number. In addition, increased calcium/calmodulin-dependent protein kinase II (CaMKII) activity was observed in the mPFC of ATRX(ΔE2) mice. Increased CaMKII autophosphorylation and activity were associated with increased phosphorylation of the Rac1-guanine nucleotide exchange factors (GEFs) Tiam1 and kalirin-7 (known substrates of CaMKII), and  increased phosphorylation of p21-activated kinases (PAKs). These findings suggest that aberrant CaMKII activation likely mediates abnormal spine formation in the mPFC. The morphological changes and elevated Rac1-GEF/PAK signaling seen in ATRX(ΔE2) mice may contribute to the ID syndrome in patients.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21209221","rdfs:label":"Atrx exon 2 deletion mice-dendritic spines","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/9d481d8b-f358-4415-8205-5e92479b6089","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8ad138dc-d92e-4a2a-9ea9-14c670eead20","type":"Finding","dc:description":"For behavioral testing (PMID: 19088125), female NestinCre ATrax mice were studied (Atrx-cHEt) which would show mosaic expression the null allele due to random X-chromosome inactivation. Deficits in memory and learning were observed in the spontaneous novel object recognition task, contextual fear task and Morris Water maze.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/19088125","rdfs:label":"Atrx floxed conditional null mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4.5},{"id":"https://genegraph.clinicalgenome.org/r/5296ecdf-b709-47bd-9032-daec8b91e300_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/01a5eb2f-adf6-45b9-8a98-e7f1068303b7","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/01a5eb2f-adf6-45b9-8a98-e7f1068303b7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/7697714","allele":{"id":"https://genegraph.clinicalgenome.org/r/356511d9-0b6a-4b12-90d9-ee5be5859142","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000489.6(ATRX):c.7162G>T (p.Glu2388Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA256039"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/b567fc0e-1138-4452-b61e-f6d9f9aa0145","type":"EvidenceLine","dc:description":"The mother is a carrier of the variant and one unaffected daughter is mentioned but excluded from the pedigree. The second affected individual was tested through amniocentesis and therefore is not described beyond carrying the variant. Per SOP version 8, there are not enough affected individuals to count this family for segregation.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b567fc0e-1138-4452-b61e-f6d9f9aa0145_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11559911","allele":{"id":"https://genegraph.clinicalgenome.org/r/abee71d5-3ae2-486a-809a-fe106b0981ac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.77698573C>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA413724354"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/ab9010b3-480c-47d1-b513-335e9013db96","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab9010b3-480c-47d1-b513-335e9013db96_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23681356","allele":{"id":"https://genegraph.clinicalgenome.org/r/c6be7e0e-9093-4081-96c6-8a1140130da7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000489.6(ATRX):c.390dup (p.Glu131ArgfsTer6)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030177"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/34b89099-7a7c-4808-ac4f-319736a3c0ed","type":"EvidenceLine","dc:description":"This is a recurrent nonsense variant.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/34b89099-7a7c-4808-ac4f-319736a3c0ed_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e6af0c-6e93-42fa-a263-e5c246c921c9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000489.6(ATRX):c.109C>T (p.Arg37Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11742"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/3aa5b5dc-75c7-4d5e-85e1-fdecaf8ffccb","type":"EvidenceLine","dc:description":"This is a recurrent nonsense variant.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3aa5b5dc-75c7-4d5e-85e1-fdecaf8ffccb_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e6af0c-6e93-42fa-a263-e5c246c921c9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/cc08c679-862d-449d-8043-e09a860fc24a","type":"EvidenceLine","dc:description":"This is a recurrent nonsense variant.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cc08c679-862d-449d-8043-e09a860fc24a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e6af0c-6e93-42fa-a263-e5c246c921c9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5296ecdf-b709-47bd-9032-daec8b91e300_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0170adc0-65d9-4cd0-8aac-ade790bd62d3_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","rdfs:label":"K8360","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/0170adc0-65d9-4cd0-8aac-ade790bd62d3","type":"Family","rdfs:label":"K8360","member":{"id":"https://genegraph.clinicalgenome.org/r/8ebcc8d8-5484-4f9c-99b4-a6409504d916","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","rdfs:label":"K8360-II:2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":28,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e6af0c-6e93-42fa-a263-e5c246c921c9"},"detectionMethod":"WES performed on the proband, followed by Sanger sequencing for confirmation. Other family members underwent Sanger sequencing of candidate gene mutation.","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001252","obo:HP_0001249","obo:HP_0001270","obo:HP_0001263","obo:HP_0004322"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/cc08c679-862d-449d-8043-e09a860fc24a_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0001249","obo:HP_0001263"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/8ebcc8d8-5484-4f9c-99b4-a6409504d916"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/aae51d06-026b-478a-b52b-44a46fd38bde_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","rdfs:label":"K9574","family":{"id":"https://genegraph.clinicalgenome.org/r/aae51d06-026b-478a-b52b-44a46fd38bde","type":"Family","rdfs:label":"K9574","member":{"id":"https://genegraph.clinicalgenome.org/r/f83ef1d7-1844-48ca-89c4-5f6182983105","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","rdfs:label":"K9574-IV:3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":36,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e6af0c-6e93-42fa-a263-e5c246c921c9"},"detectionMethod":"Next generation sequencing targeted panel of 90 known X-linked intellectual disability genes. Identified variants were validated by Sanger sequencing.","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0000252","obo:HP_0000750","obo:HP_0005280","obo:HP_0001249","obo:HP_0001250","obo:HP_0000708","obo:HP_0004322"],"previousTesting":true,"previousTestingDescription":"Found negative for Fragile X syndrome. No chromosomal abnormalities found through G-banding. Negative for RSK4 and OPHN1 gene mutations, genes within linkage interval.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/3aa5b5dc-75c7-4d5e-85e1-fdecaf8ffccb_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0001249","obo:HP_0000708"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/f83ef1d7-1844-48ca-89c4-5f6182983105"},"publishedLodScore":2.36,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/881f5b5b-9207-4f73-94d9-fe340732d3f1_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","rdfs:label":"K8820","estimatedLodScore":1.81,"family":{"id":"https://genegraph.clinicalgenome.org/r/881f5b5b-9207-4f73-94d9-fe340732d3f1","type":"Family","rdfs:label":"K8820","member":{"id":"https://genegraph.clinicalgenome.org/r/ee02056b-4a95-4a39-ac6b-31a98b87322e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","rdfs:label":"K8820-III:5","ageType":"AgeAtDiagnosis","ageUnit":"Years","ageValue":14,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e6af0c-6e93-42fa-a263-e5c246c921c9"},"detectionMethod":"Next generation sequencing targeted panel of 90 known X-linked intellectual disability genes. Identified variants were validated by Sanger sequencing.","firstTestingMethod":"Next generation sequencing panels","phenotypes":["obo:HP_0001344","obo:HP_0001263","obo:HP_0001215","obo:HP_0001252","obo:HP_0009697","obo:HP_0001249"],"previousTesting":false,"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/23b04787-1965-4b0a-bccf-ea4900b21e73_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e6af0c-6e93-42fa-a263-e5c246c921c9"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0001263","obo:HP_0001249"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/ee02056b-4a95-4a39-ac6b-31a98b87322e"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/35a992cd-3341-40c5-aa76-6cede84af675_proband_segregation","type":"FamilyCosegregation","dc:description":"published in PMID:9192265. Proband had WGS, all others candidate gene sequencing and linkage with markers.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","rdfs:label":"K8035","family":{"id":"https://genegraph.clinicalgenome.org/r/35a992cd-3341-40c5-aa76-6cede84af675","type":"Family","rdfs:label":"K8035","member":{"id":"https://genegraph.clinicalgenome.org/r/315999d8-d47c-42ca-bb6d-768cedec17bc","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24805811","rdfs:label":"K8035-III:3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":32,"allele":{"id":"https://genegraph.clinicalgenome.org/r/a6e6af0c-6e93-42fa-a263-e5c246c921c9"},"detectionMethod":"Next generation sequencing targeted panel of 90 known X-linked intellectual disability genes. Identified variants were validated by Sanger sequencing.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Walking achieved at 2 years old, speech development at 4-5 years old.","phenotypes":["obo:HP_0001284","obo:HP_0000750","obo:HP_0001263","obo:HP_0001252","obo:HP_0002857","obo:HP_0001249"],"previousTesting":false,"previousTestingDescription":"linkage analysis within the family to define the locus responsible for the disease.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/34b89099-7a7c-4808-ac4f-319736a3c0ed_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0001263","obo:HP_0001249"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/315999d8-d47c-42ca-bb6d-768cedec17bc"},"publishedLodScore":2.53,"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/d03aa87e-da82-474e-9a84-0e67d4ef5ffc","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d03aa87e-da82-474e-9a84-0e67d4ef5ffc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23681356","allele":{"id":"https://genegraph.clinicalgenome.org/r/e84b3958-6d1b-4d31-ae19-daee0d3f4312","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.77520784T>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA2497030176"}},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/23b04787-1965-4b0a-bccf-ea4900b21e73","type":"EvidenceLine","dc:description":"This is a recurrent nonsense variant.","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/23b04787-1965-4b0a-bccf-ea4900b21e73_variant_evidence_item"}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/86422c98-583e-4bf5-bafa-ef49ad5e175e","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/86422c98-583e-4bf5-bafa-ef49ad5e175e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/10204841","allele":{"id":"https://genegraph.clinicalgenome.org/r/a977bca5-d10d-4543-af5b-96430c2ae0d7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000489.6(ATRX):c.524G>A (p.Gly175Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA413722667"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Hemizygous"}},{"id":"https://genegraph.clinicalgenome.org/r/86422c98-583e-4bf5-bafa-ef49ad5e175e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Reduced levels of XNP/ATR-X and an abnormal form of the protein were identified in the western blot results. Localization of the XNP/ATR-X protein was concentrated in the nucleus as it should be and instead a diffuse XNP/ATR-X staining was observed in immunofluorescence microscopy. In vitro binding assays were performed as well which found that the variant almost completely abolished the in vitro DNA binding capacity.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/176d8c36-3a4f-4e9d-bc90-e43f7d8f21e7","type":"EvidenceLine","dc:description":"This is a recurrent missense variant, reported multiple times in ClinVar, interpreted as pathogenic/likely pathogenic (Allele ID 26774). This proband has an affected dizygotic twin. The mother is a carrier for the ATRX variant, p.Arg246Cys, confirmed by sequence analysis. Per SOP version 8, there are not enough affected individuals to count this family for segregation.","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/176d8c36-3a4f-4e9d-bc90-e43f7d8f21e7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20500465","allele":{"id":"https://genegraph.clinicalgenome.org/r/c0487cb2-abd8-4493-b01a-3dfa40dfcecf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000489.6(ATRX):c.736C>T (p.Arg246Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA204872"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":11053,"specifiedBy":"GeneValidityCriteria8","strengthScore":16.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/4fYk77NQl4U","type":"GeneValidityProposition","disease":"obo:MONDO_0016980","gene":"hgnc:886","modeOfInheritance":"obo:HP_0001417"},"version":"2.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_5296ecdf-b709-47bd-9032-daec8b91e300-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}